Physician profile
Michael James
NPI 1538161609
$4,365.10
in general payments reported to CMS, 2019-2025
47 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,801 · 2020: $438 · 2021: $205 · 2022: $573 · 2023: $562 · 2024: $379 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $415.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $294.04 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $289.59 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.68 | 2019-2024 | Stiolto Respimat, Jardiance |
| Amgen INC. | $253.71 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $251.90 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $197.62 | 2019-2025 | Spravato |
| Pfizer INC. | $189.91 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $186.99 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $184.56 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.26 | 2019-2025 | Xifaxan |
| Abbvie INC. | $121.00 | 2022-2024 | |
| Medtronic, INC. | $110.75 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Otsuka America Pharmaceutical, INC. | $106.50 | 2023-2025 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $104.27 | 2019-2025 | Capvaxive |
Show all 45 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.